Evidence map›Paper›PMID 33592027›Full record

ArticlePloS one2021

Prevalence of low high-density lipoprotein among young adults receiving antiretroviral therapy in Zambia: An opportunity to consider non-communicable diseases in resource-limited settings.

Benson M Hamooya, Patrick Musonda, Wilbroad Mutale, Sepiso K Masenga, Hikabasa Halwiindi, Katongo H Mutengo, Kaseya O R Chiyeñu, Gershom Chongwe, John R Koethe, Loren Lipworth and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Benson M HamooyaUniversity of Zambia School of Public Health, Lusaka, Zambia.ORCID 0000-0003-1385-0998
Patrick MusondaUniversity of Zambia School of Public Health, Lusaka, Zambia.
Wilbroad MutaleUniversity of Zambia School of Public Health, Lusaka, Zambia.
Sepiso K MasengaMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.
Hikabasa HalwiindiUniversity of Zambia School of Public Health, Lusaka, Zambia.
Katongo H MutengoLivingstone Central Hospital, Livingstone, Zambia.
Kaseya O R ChiyeñuLivingstone Central Hospital, Livingstone, Zambia.
Gershom ChongweUniversity of Zambia School of Public Health, Lusaka, Zambia.ORCID 0000-0003-3303-308X
John R KoetheVanderbilt Institute for Global Health, Nashville, TN, United States of America.
Loren LipworthVanderbilt University Medical Center, Nashville, TN, United States of America.
Douglas C HeimburgerVanderbilt Institute for Global Health, Nashville, TN, United States of America.ORCID 0000-0003-3551-9710
University of Zambia · ZMVanderbilt University · USMinistry of Health · ZMMulungushi University · ZM

Funding

UNZA-Vanderbilt Training Partnership for HIV-NCD Research (UVP-2)D43TW009744 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEIMBURGER, DOUGLAS CORBETT, MUTALE, WILBROAD · 2015 to 2025
$3.2M
FIC NIH HHS D43 TW009744
6 · The paper itself

Abstract

backgroundWith the introduction of effective antiretroviral therapy (ART), people living with HIV (PLWH) are surviving longer and are at risk for developing metabolic abnormalities that contribute to cardiovascular disease (CVD). In Sub-Saharan Africa (SSA), there is a paucity of epidemiological data on lipid profiles among young adults receiving ART. This study aimed to estimate the prevalence of low high-density lipoprotein cholesterol (HDL-c), a cardioprotective lipid class, and whether it differed by age among adults on ART in Livingstone, Zambia.

methodsFrom April to December 2019, we conducted a cross-sectional study of 597 PLWH [n = 58 aged 18-24 years (young adults); n = 539 aged ≥25 years (adults)] on ART for ≥6 months. Data collected included demographic and lifestyle information, anthropometrics, viral load (VL), CD4 count, blood pressure, lipid profiles and fasting/random blood glucose. Clinical measures were defined as: low HDL-c [<1.0 mmol/L for men, <1.3 for women], increased waist circumference (WC) [≥94 cm for men, ≥80 cm for women], high triglycerides (TG) [≥1.7 mmol/l], and virological failure (VF) [VL ≥1000 copies/μl]. We used logistic regression to examine the association between age and low HDL-c after adjusting for multiple variables.

resultsAmong the young adults, 60% (35/58) were women, median (25th, 75th percentile) age 21 years (18, 23), and median time on ART 116 months (60, 144). Among adults, 63% (342/539) were women, median age 46 years (40, 53) and median time on ART 108 months (60, 144). Young adults had a lower CD4 count compared to adults (median, 492 vs. 568 cells/μL, p = 0.010) and higher prevalence of VF (29% vs. 17%, p = 0.016). In young adults, prevalence of low HDL-c was significantly higher than in adults (63 vs. 38%, p<0.001). A high proportion of young adults (75%) and adults (58%) with low HDL-c were on dolutegravir (DTG)-based ART regimens. After adjusting for sex, duration on ART, WC, body mass index, ART regimen, VF, CD4 count, low density lipoprotein cholesterol, blood pressure and smoking, young adults were significantly more likely than adults to have low HDL-c (odds ratio 2.93; 95% confidence interval 1.46-5.86).

conclusionLow HDL-c is highly prevalent among young adult with HIV in SSA independent of other risk factors for metabolic derangements. Lipid abnormalities among young PLWH may contribute to the early development of cardiovascular diseases in this population. This highlights the need to consider low HDL-c in the quest to reduce CVD risk among young adults on ART in SSA.

Indexed as

Antiretroviral Therapy, Highly ActiveAdultCholesterol, LDLCross-Sectional StudiesFemaleHIV InfectionsHumansMaleMiddle AgedNoncommunicable DiseasesPrevalenceViral LoadYoung AdultZambiaCholesterol, LDL

Identifiers

PMID33592027
PMCPMC7886128
OpenAlexW3131379355

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.